TAK-915

TAK-915 is a potent, selective, brain-penetrant and orally active small molecule inhibitor of phosphodiesterase 2A (PDE2A), with an IC50 of 0.61 nM and over 4100-fold selectivity for PDE2A compared to PDE1A[1]. It was developed by Takeda for the potential treatment of neuropsychiatric and neurodegenerative disorders characterized by cognitive impairment. Preclinical studies demonstrated that TAK-915 increases cGMP levels in key brain regions and improves cognitive performance in animal models of aging and schizophrenia-related deficits[2][4]. Clinical development included phase I trials in healthy volunteers and patients with schizophrenia; however, further development for schizophrenia was discontinued after phase I[3].

Other names

N-{(1S)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide1476727-50-0UNII-0M4DME62Y9UNII0M4DME62Y9UNII 0M4DME62Y9